MENU
+Compare
CTMX
Stock ticker: NASDAQ
AS OF
Jun 6, 12:36 PM (EDT)
Price
$2.53
Change
+$0.13 (+5.42%)
Capitalization
379.68M

CTMX CytomX Therapeutics Forecast, Technical & Fundamental Analysis

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment... Show more

Industry: #Biotechnology
CTMX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for CTMX with price predictions
Jun 05, 2025

CTMX in downward trend: price may decline as a result of having broken its higher Bollinger Band on May 30, 2025

CTMX broke above its upper Bollinger Band on May 30, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 29 similar instances where the stock broke above the upper band. In of the 29 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for CTMX moved out of overbought territory on June 04, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 50 cases where CTMX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CTMX turned negative on June 05, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTMX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 29, 2025. You may want to consider a long position or call options on CTMX as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 50-day moving average for CTMX moved above the 200-day moving average on May 28, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CTMX advanced for three days, in of 252 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 90 cases where CTMX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CTMX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.798) is normal, around the industry mean (16.332). P/E Ratio (5.229) is within average values for comparable stocks, (59.787). CTMX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.227). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (1.461) is also within normal values, averaging (263.647).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTMX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
CTMX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

CTMX is expected to report earnings to fall 123.00% to -6 cents per share on August 07

CytomX Therapeutics CTMX Stock Earnings Reports
Q2'25
Est.
$-0.06
Q1'25
Beat
by $0.21
Q4'24
Beat
by $0.43
Q3'24
Beat
by $0.24
Q2'24
Beat
by $0.02
The last earnings report on May 12 showed earnings per share of 27 cents, beating the estimate of 5 cents. With 1.05M shares outstanding, the current market capitalization sits at 379.68M.
A.I. Advisor
published General Information

General Information

an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
151 Oyster Point Boulevard
Phone
+1 650 515-3185
Employees
122
Web
https://www.cytomx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TWEIX8.54N/A
N/A
American Century Equity Income Inv
FASPX43.46N/A
N/A
Fidelity Advisor Value Strategies M
KTRIX9.12N/A
N/A
DWS Global Income Builder Inst
MFMPX16.17N/A
N/A
Morgan Stanley Inst Next Gen Em Mkts A
RVPIX8.31-0.03
-0.36%
Royce Smaller-Companies Growth Instl

CTMX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CTMX has been loosely correlated with MLEC. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CTMX jumps, then MLEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CTMX
1D Price
Change %
CTMX100%
-3.98%
MLEC - CTMX
42%
Loosely correlated
N/A
CRNX - CTMX
38%
Loosely correlated
+0.59%
BCAB - CTMX
37%
Loosely correlated
-3.71%
NKTR - CTMX
36%
Loosely correlated
-9.59%
VCYT - CTMX
36%
Loosely correlated
-1.17%
More